JPWO2020065064A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020065064A5 JPWO2020065064A5 JP2021517294A JP2021517294A JPWO2020065064A5 JP WO2020065064 A5 JPWO2020065064 A5 JP WO2020065064A5 JP 2021517294 A JP2021517294 A JP 2021517294A JP 2021517294 A JP2021517294 A JP 2021517294A JP WO2020065064 A5 JPWO2020065064 A5 JP WO2020065064A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- glp
- concentration
- analogue
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024120747A JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197755.4 | 2018-09-28 | ||
| EP18197755.4A EP3628683A1 (en) | 2018-09-28 | 2018-09-28 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| PCT/EP2019/076305 WO2020065064A1 (en) | 2018-09-28 | 2019-09-27 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120747A Division JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502432A JP2022502432A (ja) | 2022-01-11 |
| JPWO2020065064A5 true JPWO2020065064A5 (https=) | 2022-09-13 |
| JP2022502432A5 JP2022502432A5 (https=) | 2022-09-13 |
| JP7566730B2 JP7566730B2 (ja) | 2024-10-15 |
Family
ID=63794308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517294A Active JP7566730B2 (ja) | 2018-09-28 | 2019-09-27 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
| JP2024120747A Active JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120747A Active JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220265551A1 (https=) |
| EP (2) | EP3628683A1 (https=) |
| JP (2) | JP7566730B2 (https=) |
| KR (2) | KR20260008798A (https=) |
| CN (3) | CN112771073B (https=) |
| AU (1) | AU2019348538B2 (https=) |
| BR (1) | BR112021005858A2 (https=) |
| CA (1) | CA3114330A1 (https=) |
| CL (1) | CL2021000678A1 (https=) |
| IL (1) | IL281362B1 (https=) |
| MX (2) | MX2021003271A (https=) |
| NZ (1) | NZ775113A (https=) |
| SG (1) | SG11202102383VA (https=) |
| WO (1) | WO2020065064A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| EP4154869A4 (en) * | 2020-05-22 | 2025-01-22 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glp-2 |
| MX2023006901A (es) * | 2020-12-16 | 2023-06-26 | Zealand Pharma As | Uso de analogos de glp-2 en pacientes con insuficiencia renal. |
| AU2022341538A1 (en) * | 2021-09-10 | 2024-04-11 | Zealand Pharma A/S | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| EP4572783A1 (en) | 2022-09-30 | 2025-06-25 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| WO2024075135A1 (en) * | 2022-10-03 | 2024-04-11 | Orbicular Pharmaceutical Technologies Private Limited | "stable injectable compositions of glp-2 peptide" |
| IL322328A (en) | 2023-01-27 | 2025-09-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ250844A (en) * | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| DE60142885D1 (de) | 1996-04-12 | 2010-10-07 | Ontario Inc 1149336 | Dem Glukagon ähnliches Peptid-2 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| ATE396202T1 (de) | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| EP2119724A1 (en) * | 2005-05-03 | 2009-11-18 | Novetide Ltd. | Solid-phase process foor the preparation of goserelin |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| CN101341254A (zh) * | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10，顺-12十八碳二烯酸的生产方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| WO2008082656A1 (en) * | 2006-12-29 | 2008-07-10 | Ipsen Pharma S.A.S. | Glp-1 pharmaceutical compositions |
| CA2798518A1 (en) * | 2010-05-17 | 2011-11-24 | Cebix, Inc. | Pegylated c-peptide |
| FR2994390B1 (fr) * | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| PT2922530T (pt) * | 2012-11-20 | 2016-12-22 | Fresenius Kabi Usa Llc | Formulações de acetato de caspofungina |
| AU2015335743B2 (en) * | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| EP4591853A1 (en) * | 2016-11-21 | 2025-07-30 | Amylyx Pharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
-
2018
- 2018-09-28 EP EP18197755.4A patent/EP3628683A1/en not_active Withdrawn
-
2019
- 2019-09-27 AU AU2019348538A patent/AU2019348538B2/en active Active
- 2019-09-27 JP JP2021517294A patent/JP7566730B2/ja active Active
- 2019-09-27 US US17/276,252 patent/US20220265551A1/en active Pending
- 2019-09-27 NZ NZ775113A patent/NZ775113A/en unknown
- 2019-09-27 CN CN201980063594.1A patent/CN112771073B/zh active Active
- 2019-09-27 CN CN202510255078.6A patent/CN120204366A/zh active Pending
- 2019-09-27 KR KR1020257041229A patent/KR20260008798A/ko active Pending
- 2019-09-27 CN CN202410277209.6A patent/CN118267455A/zh active Pending
- 2019-09-27 KR KR1020217010775A patent/KR20210069056A/ko not_active Ceased
- 2019-09-27 SG SG11202102383VA patent/SG11202102383VA/en unknown
- 2019-09-27 WO PCT/EP2019/076305 patent/WO2020065064A1/en not_active Ceased
- 2019-09-27 EP EP19773860.2A patent/EP3856766A1/en active Pending
- 2019-09-27 MX MX2021003271A patent/MX2021003271A/es unknown
- 2019-09-27 BR BR112021005858-3A patent/BR112021005858A2/pt unknown
- 2019-09-27 CA CA3114330A patent/CA3114330A1/en active Pending
-
2021
- 2021-03-09 IL IL281362A patent/IL281362B1/en unknown
- 2021-03-19 MX MX2026000859A patent/MX2026000859A/es unknown
- 2021-03-19 CL CL2021000678A patent/CL2021000678A1/es unknown
-
2023
- 2023-10-16 US US18/487,666 patent/US20240065978A1/en active Pending
-
2024
- 2024-07-26 JP JP2024120747A patent/JP7738136B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6111475B2 (ja) | ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物 | |
| HK1248607A1 (zh) | Ph为7且至少含pi为5．8至8．5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 | |
| AU2019348538B2 (en) | Formulations of glucagon-like-peptide-2 (GLP-2) analogues | |
| JP7847615B2 (ja) | １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 | |
| ES2896971T3 (es) | Formas de administración de hormona del crecimiento de acción prolongada | |
| JP2014524480A5 (https=) | ||
| US20190060410A1 (en) | Pharmaceutical Formulation Comprising GLP-1 Analogue and Preparation Method Thereof | |
| JPWO2020065064A5 (https=) | ||
| JP2021519321A5 (https=) | ||
| EP3856767B1 (en) | Formulations of glucagon-like-peptide-2 (glp-2) analogues | |
| JP2017517561A (ja) | 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性 | |
| JP2004513069A (ja) | ペプチド医薬処方 | |
| EP4398872B1 (en) | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues | |
| EP4536691A1 (en) | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management | |
| RU2021106892A (ru) | Составы аналогов глюкагоноподобного пептида-2 (glp-2) | |
| CA2872953C (en) | Parenteral esmolol formulation | |
| JPWO2019191264A5 (https=) | ||
| RU2833459C2 (ru) | Составы аналогов глюкагоноподобного пептида-2 (glp-2) | |
| HK40108236A (en) | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues | |
| HK40108236B (en) | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues | |
| WO2026083250A1 (en) | Article of manufacture for semaglutide compositions | |
| WO2025141472A1 (en) | Stable pharmaceutical compositions comprising tirzepatide | |
| WO2026013454A1 (en) | Multi-dose pen of tirzepatide | |
| BR112015011179B1 (pt) | Composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação |